Recently, using the Breakthrough Devices Program, UCH-L1 and GFAP were approved by the Food and Drug Administration (FDA) as the first blood-based biomarker called the Brain Trauma IndicatorTM (BTITM) [23]. Here, GFAP is linked to brain injury.